JP2017533928A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533928A5 JP2017533928A5 JP2017525587A JP2017525587A JP2017533928A5 JP 2017533928 A5 JP2017533928 A5 JP 2017533928A5 JP 2017525587 A JP2017525587 A JP 2017525587A JP 2017525587 A JP2017525587 A JP 2017525587A JP 2017533928 A5 JP2017533928 A5 JP 2017533928A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- organ
- alkyl
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 68
- 150000003839 salts Chemical class 0.000 claims description 55
- 210000000056 organ Anatomy 0.000 claims description 47
- 239000003814 drug Substances 0.000 claims description 29
- 210000001519 tissue Anatomy 0.000 claims description 20
- 239000003550 marker Substances 0.000 claims description 13
- 210000003491 skin Anatomy 0.000 claims description 13
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 10
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 10
- 230000017423 tissue regeneration Effects 0.000 claims description 9
- 210000000845 cartilage Anatomy 0.000 claims description 8
- 210000002216 heart Anatomy 0.000 claims description 8
- 210000000936 intestine Anatomy 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 210000003205 muscle Anatomy 0.000 claims description 8
- 210000002784 stomach Anatomy 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 5
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 5
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 5
- 230000003712 anti-aging effect Effects 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 230000008467 tissue growth Effects 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 102000005741 Metalloproteases Human genes 0.000 claims description 4
- 108010006035 Metalloproteases Proteins 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 230000008520 organization Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 29
- 230000001737 promoting effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462078704P | 2014-11-12 | 2014-11-12 | |
| US62/078,704 | 2014-11-12 | ||
| PCT/CA2015/000572 WO2016074068A1 (en) | 2014-11-12 | 2015-11-12 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533928A JP2017533928A (ja) | 2017-11-16 |
| JP2017533928A5 true JP2017533928A5 (https=) | 2018-12-20 |
| JP6720169B2 JP6720169B2 (ja) | 2020-07-08 |
Family
ID=55953490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525587A Expired - Fee Related JP6720169B2 (ja) | 2014-11-12 | 2015-11-12 | 組織の自己修復及び再生のための置換芳香族化合物及び医薬組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10391073B2 (https=) |
| EP (1) | EP3217968A4 (https=) |
| JP (1) | JP6720169B2 (https=) |
| KR (1) | KR20170072352A (https=) |
| CN (1) | CN107106526B (https=) |
| AR (1) | AR102634A1 (https=) |
| AU (2) | AU2015345943B2 (https=) |
| BR (1) | BR112017009899A2 (https=) |
| CA (1) | CA2967499C (https=) |
| IL (1) | IL252221B (https=) |
| MX (1) | MX381687B (https=) |
| MY (1) | MY187515A (https=) |
| PH (1) | PH12017500856A1 (https=) |
| RU (1) | RU2728782C2 (https=) |
| SG (1) | SG11201703741TA (https=) |
| TW (1) | TWI723967B (https=) |
| UY (1) | UY36399A (https=) |
| WO (1) | WO2016074068A1 (https=) |
| ZA (1) | ZA201703579B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI742541B (zh) * | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| KR20170072352A (ko) * | 2014-11-12 | 2017-06-26 | 프로메틱 파마 에스엠티 리미티드 | 조직 자가-회복 및 재생을 위한 치환된 방향족 화합물 및 약제학적 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2289417C1 (ru) * | 2005-04-15 | 2006-12-20 | Равиль Шамилевич Мирхайдаров | Способ биологического омоложения кожи |
| EP1953222A1 (en) * | 2007-01-24 | 2008-08-06 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improvement of cell growth |
| CA2761061A1 (en) * | 2009-05-04 | 2010-11-11 | Prometic Biosciences Inc. | Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof |
| EA022445B1 (ru) | 2009-05-04 | 2016-01-29 | Прометик Байосайенсиз Инк. | Замещенные ароматические соединения, композиции на их основе и их фармацевтические применения |
| ES2351005B1 (es) * | 2009-07-10 | 2011-11-18 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de anhidrasa carbónica ii para la elaboración de un medicamento. |
| CN105997967B (zh) | 2010-10-27 | 2019-08-23 | 普罗米蒂克医药Smt有限公司 | 用于治疗癌症的化合物和组合物 |
| WO2012097428A1 (en) * | 2010-10-27 | 2012-07-26 | Prometic Biosciences Inc. | Compounds and pharmaceutical compositions for uses in diabetes |
| PT2632885T (pt) | 2010-10-27 | 2018-04-04 | Prometic Pharma Smt Ltd | Compostos carboxilatos de fenilcetona e usos farmacêuticos destes |
| JP5388233B2 (ja) * | 2011-01-19 | 2014-01-15 | 富士ソフト株式会社 | 再生軟骨の軟骨特性を評価する方法 |
| CA2844792A1 (en) * | 2011-08-10 | 2013-02-14 | Digna Biotech, S.L. | Use of cardiotrophin-1 for the treatment of kidney diseases |
| TWI689490B (zh) | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療纖維化之經取代之芳族化合物及相關方法 |
| TWI742541B (zh) | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| BR112017007426A2 (pt) * | 2014-10-10 | 2018-01-16 | Prometic Pharma Smt Limited | compostos aromáticos substituídos e composições farmacêuticas para prevenir e tratar osteoporose |
| KR20170066614A (ko) * | 2014-10-10 | 2017-06-14 | 프로메틱 파마 에스엠티 리미티드 | 당뇨병의 예방 및 치료를 위한 치환된 방향족 화합물 및 약제학적 조성물 |
| KR20170072352A (ko) * | 2014-11-12 | 2017-06-26 | 프로메틱 파마 에스엠티 리미티드 | 조직 자가-회복 및 재생을 위한 치환된 방향족 화합물 및 약제학적 조성물 |
-
2015
- 2015-11-12 KR KR1020177015741A patent/KR20170072352A/ko not_active Ceased
- 2015-11-12 MX MX2017006281A patent/MX381687B/es unknown
- 2015-11-12 US US15/526,405 patent/US10391073B2/en not_active Expired - Fee Related
- 2015-11-12 AR ARP150103693A patent/AR102634A1/es unknown
- 2015-11-12 BR BR112017009899-7A patent/BR112017009899A2/en active Search and Examination
- 2015-11-12 EP EP15859768.2A patent/EP3217968A4/en not_active Withdrawn
- 2015-11-12 CA CA2967499A patent/CA2967499C/en active Active
- 2015-11-12 UY UY0001036399A patent/UY36399A/es unknown
- 2015-11-12 TW TW104137375A patent/TWI723967B/zh not_active IP Right Cessation
- 2015-11-12 RU RU2017120401A patent/RU2728782C2/ru active
- 2015-11-12 MY MYPI2017000688A patent/MY187515A/en unknown
- 2015-11-12 CN CN201580071284.6A patent/CN107106526B/zh not_active Expired - Fee Related
- 2015-11-12 SG SG11201703741TA patent/SG11201703741TA/en unknown
- 2015-11-12 WO PCT/CA2015/000572 patent/WO2016074068A1/en not_active Ceased
- 2015-11-12 AU AU2015345943A patent/AU2015345943B2/en not_active Ceased
- 2015-11-12 JP JP2017525587A patent/JP6720169B2/ja not_active Expired - Fee Related
-
2017
- 2017-05-08 PH PH12017500856A patent/PH12017500856A1/en unknown
- 2017-05-10 IL IL252221A patent/IL252221B/en unknown
- 2017-05-24 ZA ZA2017/03579A patent/ZA201703579B/en unknown
-
2019
- 2019-07-12 US US16/510,581 patent/US10869849B2/en active Active
-
2020
- 2020-06-19 AU AU2020204112A patent/AU2020204112B2/en not_active Ceased
- 2020-12-03 US US17/111,146 patent/US20210085626A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5775545B2 (ja) | 増殖性障害を治療するための化合物 | |
| BRPI0413930A (pt) | composto oligomérico ou sal farmaceuticamente aceitável deste, composição farmacêutica ou veterinária, métodos para inibir a expressão de eif4e em uma célula, tecido ou órgão, para diminuir a proliferação de uma célula em que eif4e é expressado, e para prevenir ou tratar uma condição ou doença métodos para prevenir ou diminuir a angiogênese, e o crescimento de tumor em um paciente, oligonucleotìdeo de anti-sentido, composição farmacêutica ou veterinária, e, uso de um composto oligomérico ou sal farmaceuticamente aceitável deste | |
| RU2013155586A (ru) | [1,3]оксазины | |
| RU2012120760A (ru) | Новые композиции для предупреждения и/или лечения лизосомных болезней накопления | |
| ES2664951T5 (es) | Composiciones que comprenden glicosaminoglicanos de baja viscosidad y uso de dicha composición en terapia de cistitis crónica | |
| JP2017523175A (ja) | ジメチルアニリン類長鎖化合物、及びその調製、自己組織化構造及び用途 | |
| RU2012135698A (ru) | Способ и композиция | |
| JP2008510758A5 (https=) | ||
| RU2007145489A (ru) | Фармацевтические композиции и способы лечения рака и его метастазов | |
| JP2018537514A5 (https=) | ||
| JP2017533928A5 (https=) | ||
| JP2021530482A5 (https=) | ||
| JP2017537140A5 (https=) | ||
| RU2013107659A (ru) | ИНГИБИТОР КАЗЕИНКИНАЗЫ 1δ И КАЗЕИНКИНАЗЫ 1ε | |
| JP2011516572A5 (https=) | ||
| RU2017120401A (ru) | Замещенные ароматические соединения и фармацевтические композиции для ауторепарации и регенерации ткани | |
| US20110269784A1 (en) | Use of tetrahydropyrimidines | |
| CN102488709B (zh) | 氟苯尼考锌螯合物注射液及其制备方法 | |
| JP2019504827A (ja) | ポリヒドロキシ化ベンゾフェノンの組成物及び神経変性障害の処置方法 | |
| CN1921855A (zh) | 用于选择性增强心房收缩力以及治疗心功能不全的kv1.5－阻滞剂 | |
| CN103889410B (zh) | 用于治疗皮肤损伤的络合的锌和α-氯羧酸化合物 | |
| US20250376466A1 (en) | Ester compounds and use thereof | |
| RU2462176C1 (ru) | Способ прямого ишемического прекондиционирования тканей внутренних органов | |
| JP2013518917A5 (https=) | ||
| RU2328298C1 (ru) | Способ лечения неспецифического язвенного колита |